The U.S. Court of Appeals for the Seventh Circuit recently issued a significant ruling regarding fraudulent joinder in a case involving claims against Mead Johnson & Company LLC and Abbott Laboratories. The court's decision, made on July 28, 2026, affects several families whose premature infants developed serious medical conditions after being fed cow's milk-based infant formula. This ruling clarifies how courts should assess the intent of plaintiffs in such cases and what constitutes fraudulent joinder.
The case, Shondera Drayton v. Mead Johnson & Company LLC, is part of a larger multidistrict litigation (MDL) concerning the alleged harmful effects of infant formulas. The court's decision is important for families seeking justice in similar situations, as it addresses the legal standards surrounding jurisdiction and the ability of plaintiffs to pursue claims in state versus federal court.
Background
The plaintiffs in this case are parents of infants who were born prematurely at Pennsylvania Hospital and subsequently developed necrotizing enterocolitis (NEC), a serious gastrointestinal disorder. The infants were fed either Similac or Enfamil, both cow's milk-based formulas produced by Abbott and Mead Johnson. The parents claim that the manufacturers failed to warn them about the risks associated with these products.
The cases were initially filed in Pennsylvania state court but were later removed to federal court by the defendants. The district court initially ruled that it lacked jurisdiction because the plaintiffs had viable claims against Pennsylvania Hospital, a non-diverse defendant. However, after further proceedings, the district court determined that the plaintiffs had fraudulently joined the hospital to defeat diversity jurisdiction, leading to the appeal.
The Ruling
The Seventh Circuit Court, led by Judge Ripple, reversed the district court's decision. The court held that the lower court's reasoning for finding fraudulent joinder was not consistent with established legal standards. The court stated, "The district court’s view of the fraudulent joinder doctrine is not consistent with the case law of the Supreme Court or of the courts of appeals, including this court."
The court clarified that fraudulent joinder can only be established in two situations: when a plaintiff misrepresents jurisdictional facts or when there is no chance of success against the non-diverse defendant. The Seventh Circuit found that the plaintiffs had not shown a lack of intent to pursue their claims against Pennsylvania Hospital, and therefore, the lower court's ruling was incorrect.
Impact
This ruling has significant implications for the ongoing litigation involving Mead Johnson and Abbott Laboratories. By clarifying the standards for fraudulent joinder, the Seventh Circuit has reinforced the importance of protecting a plaintiff's choice of forum. This decision may encourage other plaintiffs in similar situations to pursue their claims without fear of being dismissed based on perceived lack of intent.
The ruling also highlights the challenges faced by courts dealing with complex litigation involving multiple defendants and jurisdictions. It emphasizes the need for clear legal standards to ensure fairness in the judicial process. Families affected by NEC and similar conditions may find renewed hope in their pursuit of justice against large corporations.